Abivax S.A. (ABVX) Revenue History
Annual and quarterly revenue from 2014 to present
ABVX Revenue Over Time (2014–2024)
ABVX Revenue Growth History
7 of 10 years with positive growth- FY2014 revenue growth
- N/A
- FY2015 revenue growth
- +200.0%
- FY2016 revenue growth
- +202.4%
- FY2017 revenue growth
- -92.1%
- FY2018 revenue growth
- +80.0%
- FY2019 revenue growth
- -88.9%
- FY2020 revenue growth
- +3050.0%
- FY2021 revenue growth
- -41.3%
- FY2022 revenue growth
- +12286.5%
- FY2023 revenue growth
- +0.8%
- FY2024 revenue growth
- +133.5%
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2025 | $2.0M | -40.6% |
| Q4 2024 | $7.4M | +218.1% |
| Q2 2024 | $3.4M | +50.9% |
| Q4 2023 | $2.3M | +3.5% |
| Q2 2023 | $2.2M | +0.9% |
| Q4 2022 | $2.2M | — |
| Q2 2022 | $2.2M | — |
| Q4 2021 | $0 | — |
ABVX Revenue Analysis (2014–2024)
Current Revenue & Growth
As of June 12, 2026, Abivax S.A. (ABVX) generated trailing twelve-month (TTM) revenue of $15.1 million, reflecting significant decline in growth of -40.6% year-over-year. The most recent quarter (Q2 2025) recorded $2.0 million in revenue, down 72.7% sequentially.
Historical Growth Trajectory
ABVX's 5-year compound annual growth rate (CAGR) stands at +457.7%, indicating outstanding long-term growth trajectory. The 3-year CAGR of +563.2% exceeds the 5-year average, indicating an acceleration in the most recent period. Abivax S.A.'s highest annual revenue of $10.8 million was recorded in 2024, an all-time high.
Peer Comparison
Compared to Healthcare sector peers — including ARRY (+13.2% YoY), PTGX (-91.5% YoY), and PRTA (-58.0% YoY) — ABVX has underperformed the peer group in revenue growth. Compare ABVX vs ARRY →
ABVX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
 ABVXCurrent | $15M | -40.6% | +457.7% | -1602.9% | |
 ARRY | $1.3B | +13.2% | +8.0% | 6.6% | |
 PTGX | $46M | -91.5% | +10.0% | -343.6% | |
 PRTA | $10M | -58.0% | +62.6% | -1905.8% | |
 ARDX | $407M | +18.2% | +121.9% | -10.1% |
ABVX Historical Revenue Data (2014–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $10.8M | +133.5% | $10.8M | 100.0% | $-172,984,000 | -1602.9% |
| 2023 | $4.6M | +0.8% | $4.6M | 99.0% | $-127,376,000 | -2756.5% |
| 2022 | $4.6M | +12286.5% | $4.5M | 97.6% | $-64,836,000 | -1414.7% |
| 2021 | $37K | -41.3% | $-119,000 | -321.6% | $-41,400,000 | -111891.9% |
| 2020 | $63K | +3050.0% | $-33,769,000 | -53601.6% | $-38,008,000 | -60330.2% |
| 2019 | $2K | -88.9% | $-28,186,000 | -1409300.0% | $-33,296,000 | -1664800.0% |
| 2018 | $18K | +80.0% | $-50,000 | -277.8% | $-19,108,000 | -106155.6% |
| 2017 | $10K | -92.1% | $-6,000 | -60.0% | $-14,150,000 | -141500.0% |
| 2016 | $127K | +202.4% | $-14,518,000 | -11431.5% | $-18,236,000 | -14359.1% |
| 2015 | $42K | +200.0% | $-303,000 | -721.4% | $-18,255,000 | -43464.3% |
| 2014 | $14K | - | $-3,265,000 | -23321.4% | $-5,054,000 | -36100.0% |
What if you invested $1,000 in ABVX back in 2014?
Total return with dividends reinvested · 12+ years of data
Calculate ReturnsHow much would $100/month in ABVX be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs ABVX Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationABVX vs DBVT — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs DBV Technologies S.A..
Compare NowABVX — Frequently Asked Questions
Quick answers to the most common questions about buying ABVX stock.
Is ABVX's revenue growth accelerating or slowing?
ABVX revenue is declining -40.6% year-over-year. TTM revenue fell to $15M, contrasting with the 5-year CAGR of +457.7%. The reversal reflects either macro headwinds or company-specific challenges.
What is ABVX's revenue history from 2014 to 2026?
Abivax S.A. (ABVX) revenue history spans 2014 to 2026. TTM revenue as of 2026 is $15M, growing at -40.6% YoY. The 5-year CAGR is +457.7%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is ABVX's long-term revenue growth rate (CAGR)?
Abivax S.A.'s 5-year revenue CAGR of +457.7% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -40.6% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for ABVX.
Why does ABVX's quarterly revenue fluctuate?
ABVX quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Abivax S.A.'s revenue data from 2014 to 2026 shows full historical quarterly detail on this page.
How is ABVX's revenue distributed by segment?
ABVX reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does ABVX's revenue compare to industry peers?
Abivax S.A. (ABVX) with TTM revenue of $15M and -40.6% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.